Sperimentazione in fase di reclutamento = ; Sperimentazione in corso = ; Sperimentazione conclusa = ; Finanziato da un ente associato a IRDiRC = ; Studio che coinvolge i membri delle ERN in almeno due Stati =

Sperimentazioni cliniche nazionali

FRANCIA

AUVERGNE-RHONE-ALPES
BRON

BABH Study: Efficacy and Safety of Bevacizumab on Severe Bleedings Associated With Hemorrhagic Hereditary Telangiectasia (HHT). A National, Multicenter Phase III Study

CHU de Lyon HCL - GH Est-Hôpital Femme Mère Enfant

Service de génétique

Ulteriori dettagli

FRANCIA

AUVERGNE-RHONE-ALPES
CLERMONT-FERRAND

PROPLACO-Tel: Prospective Study of Antiplatelet and Anticoagulation Therapy in Hereditary Haemorrhagic Telangiectasia -FR

CHU de Clermont-Ferrand - Hôpital Gabriel Montpied

CHU Clermont Ferrand

Ulteriori dettagli

GERMANIA

Bayern
REGENSBURG

Der Einfluss von Timolol Nasenspray auf Epistaxis bei Morbus Osler Patienten

Universitätsklinikum Regensburg

Klinik und Poliklinik für Hals-Nasen-Ohren-Heilkunde

Ulteriori dettagli

ITALIA

LOMBARDIA
PAVIA

THALI-HHT: Efficacia del Talidomide nel trattamento della Telangiectasia emmorragica ereditaria - IT

Fondazione IRCCS Policlinico San Matteo

Clinica Medica III

Ulteriori dettagli

PAESI BASSI

Gelderland
NIJMEGEN

An Uncontrolled, Pilot-study Assessing the Efficacy of Octreotide Long-acting Release to Decrease Transfusion Requirements and Endoscopy Frequency in Patients With Rendu-Osler-Weber and Gastrointestinal Bleeding

Radboudumc - Radboud universitair medisch centrum

Afdeling Maag-, Darm- en Leverziekten

Ulteriori dettagli

SPAGNA

Cataluña
L'HOSPITALET DE LLOBREGAT

A Randomised, Placebo Controlled, Double Blind, Multicentre Proof of Concept Study to Assess the Safety and Efficacy of Two Doses of VAD044 in Patients With Hereditary Hemorrhagic Telangiectasia (HHT) - ES

Hospital Universitari de Bellvitge

Unidad de Enfermedades Minoritarias

Ulteriori dettagli